

Pace Analytical Life Sciences and Wolfe Laboratories join forces

20 December 2017 | News

Pace Analytical Life Sciences and Wolfe Laboratories join forces Financial terms of the transaction were not disclosed



Pace Analytical Services, LLC has announced the acquisition of Wolfe Laboratories, Inc., a leading translational contract drug development company in the Boston area. The combined capabilities of the two organizations now offer the life science industry a one-stop-shop providing formulation, process development, and analytical and CMC testing for complex molecules, from discovery through Phase 3 development and post approval. Financial terms of the transaction were not disclosed.

Wolfe Laboratories brings a whole new synergistic dimension to our life science analytics business, providing expertise in new, exciting and complex molecules in the pipelines today," commented Greg Kupp, Vice President and COO of Pace Analytical Life Sciences. "Its reputation as the partner of choice for the most advanced and cutting-edge drug modalities reinforces Pace's mission of providing solutions that bring real value to clients. We welcome Janet and her highly respected scientific teams to the Pace family."

"This partnership with Pace provides us with the resources to grow and meet the expanding needs of our amazing group of biopharmaceutical and pharmaceutical customers as we are now able to provide end-to-end support, from early stage CMC development to post commercialization GMP testing on oligonucleotides, biologics, and small molecules," commented Janet Wolfe, Founder of Wolfe Laboratories.